# MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer

> **NCT02041481** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 26 (actual)

## Conditions studied

- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer

## Interventions

- **DRUG:** MEK inhibitor MEK162
- **DRUG:** leucovorin calcium
- **DRUG:** fluorouracil
- **DRUG:** oxaliplatin
- **OTHER:** pharmacological study
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02041481
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2018-01-19
- **Final completion:** 2018-01-19
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-01-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02041481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02041481, "MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02041481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*